The modest anti-clotting effect of amla may be preferred to aspirin and anti-clotting drugs.
By Robby Gardner, Associate Editor
Amla may not have as extreme effects on blood clotting as aspirin, but the greenish fruit seems to hold one advantage while modestly reducing blood clots: a lower risk of induced bleeding.
In a crossover trial on amla extract and blood clots, researchers assigned type 2 diabetics to a daily dose of amla extract, aspirin, or clopidogrel (known commercially as Plavix) for 10 days. Amla extract was associated with a 36% reduction in platelet aggregation, or blood clotting. Both drugs provided upwards of 50% reduced blood clotting, but the greater reductions might not be ideal.
Multiple studies, including a large cohort published in the European Heart Journal, suggest a connection between platelet reductions, anti-clotting drugs, and bleeding events. A recent study on women with "heavy" menstrual bleeding identified platelet function defects in one-third of them. A milder reduction of blood clots-say, with amla-could accomplish the anti-clotting effect with less bleeding and other potential drug side effects.
The study on amla extract and blood clotting is not the first to compare the fruit product to a drug. In another 2013 trial, amla and statin both improved endothelial function and lowered inflammation compared to placebo. Both studies utilized Capros, a water-soluble amla extract from Natreon Inc. (New Brunswick, NJ).
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.